TAK-020

Cat. No.: HY-132879 CAS No.: 1627603-21-7 Molecular Formula: $C_{18}H_{17}N_{5}O_{3}$ Molecular Weight: 351.36 Btk Target:

Pathway: Protein Tyrosine Kinase/RTK Storage:

Powder -20°C 3 years 2 years -80°C In solvent 6 months

> -20°C 1 month

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: 20.83 mg/mL (59.28 mM; ultrasonic and warming and heat to 80°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.8461 mL	14.2304 mL	28.4608 mL
	5 mM	0.5692 mL	2.8461 mL	5.6922 mL
	10 mM	0.2846 mL	1.4230 mL	2.8461 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.67 mg/mL (4.75 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1.67 mg/mL (4.75 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1.67 mg/mL (4.75 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

TAK-020 is a covalent Btk inhibitor, which becomes the clinical candidate.

REFERENCES

[1]. Sabat M, et al. Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-

1,2,4-1118201-3-011e, by Fragmet	ni-based Drug Design. J Med	a Cnem. 2021 Sep 9;64(17):12893	-12902.		
	Caution: Product has r	not been fully validated for m	nedical applications. For resear	ch use only	
	Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemE		
			nouth Junction, NJ 08852, USA		

Page 2 of 2 www.MedChemExpress.com